Fingerprint
Dive into the research topics of 'A phase 3 randomized study (HOMER) of ofatumumab vs rituximab in iNHL relapsed after rituximab-containing therapy'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
A phase 3 randomized study (HOMER) of ofatumumab vs rituximab in iNHL relapsed after rituximab-containing therapy
David G. Maloney, Michinori Ogura, Noriko Fukuhara, Jaclyn Davis, Janet Lasher, Miguel Izquierdo, Hiya Banerjee, Kensei Tobinai
Research output: Contribution to journal › Article › peer-review
26
Scopus
citations